膀胱癌的MRI诊断价值

目的:总结膀胱癌的MRI征象,探讨MRI对膀胱癌分期的作用及鉴别诊断要点。方法:对探讨经手术与病理证实23例膀胱癌的MRI回顾性对比分析。其中男性,19例,女性,4例,年龄50~90岁,平均年龄70岁。18例行MRI增强检查。结果:膀胱三角区及膀胱后侧壁是最常见好发部位,表现为膀胱壁突向腔内肿块和(或)膀胱壁局限性不规则增厚;肿瘤平扫T1WI等或略高信号,T2WI呈高信号,Gd-DTPA动态增强早期肿块显著强化。根椐肿瘤生长方式可分为:①小结节型,②广基肿块型,③浸润型。MRI对膀胱癌定位、定性诊断正确率分别为95.7%(22/23)、91.3%(21/23);术前MRI诊断与TNM分期符合率为82.3%(19/23),MRI较病理分期偏高。结论:膀胱癌的MRI表现具有独特性。T1加权主要用于肿瘤的定性诊断,T2加权主要用于肿瘤的术前分期;MRI检查多方位、多序列成像,是显示膀胱癌最理想的检查方法。     

重症急性胰腺炎预防性抗生素治疗的荟萃分析

目的通过对有关文献的荟萃分析,探讨预防性抗生素治疗在重症急性胰腺炎(SAP)中的作用.方法检索1966年到2004年8月期间发表的有关预防性抗生素治疗SAP的作用方面的随机对照临床试验(RCT).按照入选标准,有6项临床试验纳入本研究,由2名作者各自独立地对入选研究中有关试验设计、研究对象的特征、研究结果等内容进行摘录,并用RevMan4.2软件进行分析.结果在SAP患者中,使用能在胰腺组织中达到有效浓度的广谱抗生素并不能减少胰腺感染(RR ＝ 0.77,95%可信区间为0.48 ～ 1.24,P ＝ 0.28),也不能减少手术干预(RR ＝ 0.84,95%可信区间为0.40～1.74,P ＝ 0.64),更不能降低死亡率(RR ＝ 0.54,95%可信区间为0.28 ～ 1.04,P ＝ 0.07),只有胰外感染的发生率有一定的减少(RR ＝ 0.52,95%可信区间为0.31 ～ 0.88,P ＝ 0.01).结论不建议在SAP患者中不加选择地预防性使用抗生素,但对于CT证实的坏死性胰腺炎,可以考虑抗生素预防性治疗.     

强脉冲光治疗浅表(皮肤)血管瘤临床观察

目的：观察强脉冲光（IPL）治疗浅表（皮肤）血管瘤的疗效。方法：选择60例浅表（皮肤）血管瘤患者,随机分为治疗组和对照组,治疗组用535nm、580nm强脉冲光治疗皮损,每三周治疗一次,三次为一个疗程;对照组采用波长为532nm的Q开关Nd：YAG激光治疗,每两周治疗一次,三次为一个疗程。观察两组皮损的治愈率、并发症等情况,并行统计学处理。结果：治疗组皮损三次治愈率明显高于对照组（P〈0.01）,患处瘢痕形成及炎症性色素沉着发生率均低于对照组。结论：强脉冲光（IPLTM）治疗浅表（皮肤）血管瘤效果满意。     

数字图书馆的个性化信息服务

分析了国内外数字图书馆个性化信息服务的现状及相关技术,提出了建立个性化信息服务系统的方法及个性化信息服务中需要注意的问题.     

大肠癌患者血清MMP-9与VEGF水平的变化及意义

目的本文检测血管内皮生长因子(VEGF)和基质金属蛋白酶(MMP-9)在大肠癌患者血清中的水平,探讨其与大肠癌恶性程度、浸润、转移的关系。方法用ELISA法对48例大肠癌患者及40例正常对照者血清VEGF和MMP-9进行检测。结果大肠癌患者血清VEGF、MMP-9的水平分别为(665.8±232.8)ng/L;(532.7±208.9)ug/L。显著高于对照组(391.6±135.2)ng/L;(317.8±132.2)ug/L(P<0.01)。并与组织分化程度、Duke’s分期有关。低分化者及C、D期患者较中、高度分化及A、B期高(P<0.01)。结论大肠癌患者血清VEGF和MMP-9水平增高,与肿瘤的组织分化程度、转移、分期有关,提示VEGF、MMP-9对大肠癌恶性程度的判断有一定的价值。     

Primary carcinoma of gallbladder in Yazd, Iran: A 14-year study (1992–2006)

Aim: To investigate the clinico‐pathological profile and stage of disease at presentation of patients with carcinoma of the gallbladder diagnosed during 1992–2006 in Iran. Methods: During this study period 34 consecutive patients with gallbladder carcinoma were identified using a pathology‐based tumor database. The data extracted for each study patient included their gender, age at diagnosis, signs and symptoms, presence of gallstones and histopathological pattern of the gallbladder carcinoma and the UICC/AJCC TNM staging system was used for labeling the stages of the disease. Results: The median age of the 34 patients studied was 69.50 with most between 61 and 70 years of age. The age range of the men was between 53 and 80 years with a median age of 71.50 years and that of the women was between 33 and 79 years with a median age of 68.50 years. The most common symptom was pain in the right hypochondrium. More women had gallstones (15/34) than men (3/10). Adenocarcinoma was the most common histopathological type (91.18%) with the commonest subtype being papillary (47.06%). Eighteen patients had stage IB and stage IIA (52.94%) carcinomas whereas stages IIB and III were observed in six (17.6%) and seven cases (20.6%), respectively. Only three cases (8.82%) were seen in stage IV. The follow up of gall bladder carcinoma (GBC) patients in this study ranged from 6 to 60 months. However, there was a progressive reduction of patients attending follow‐up oncology clinic, particularly by those who had stages III and IV of the disease. Conclusion: Most patients (52.94%) presented with early disease (stage IB and IIA) which carries a good prognosis. Early detection of GBC and a national consensus for the evidence‐based management of GBC in Iran should be the major components of a strategy aimed at improving therapeutic outcome.     

The use of recombinant-activated factor VII in von Willebrand disease: a case series.

Spontaneous and surgery-associated bleeding in patients with von Willebrand disease (vWD) cannot always be controlled with desmopressin or replacement therapy. This paper presents results on the use of recombinant-activated factor VII (rFVIIa) in patients with vWD included in the internet registry Haemostasis.com. Twenty-eight reports on the use of rFVIIa in vWD were identified from the database and included in this analysis. The bleeding episodes were classified as mild (n = 7), moderate (n = 16), or severe (n = 2), and were unspecified in three cases. The median dose of rFVIIa administered was 94 microg/kg body weight (40-127.3 microg/kg). Bleeding stopped in 23 of 27 evaluable patients (85%) and markedly decreased in three patients; the total response rate was 96% (26/27 patients). Response did not correlate with the type of vWD, the site or severity of the initial bleed, or the rFVIIa dose. Other replacement therapies were infrequently used, and their use was similar in the 24 h before and after rFVIIa administration. Eighteen patients also received antifibrinolytic treatment, but its impact on response was not recorded. Only one adverse event (mild fever) was observed. These cases suggest a role for rFVIIa as a safe and effective therapy for vWD.